DE69431050T2 - PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN - Google Patents

PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN

Info

Publication number
DE69431050T2
DE69431050T2 DE69431050T DE69431050T DE69431050T2 DE 69431050 T2 DE69431050 T2 DE 69431050T2 DE 69431050 T DE69431050 T DE 69431050T DE 69431050 T DE69431050 T DE 69431050T DE 69431050 T2 DE69431050 T2 DE 69431050T2
Authority
DE
Germany
Prior art keywords
neurological disorders
benzodiazepinone
pyrido
receptor ligand
treating neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69431050T
Other languages
English (en)
Other versions
DE69431050D1 (de
Inventor
R Tyler Mccabe
R Wilson
A Rhodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Pharmaceutical Discovery Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Discovery Corp filed Critical Pharmaceutical Discovery Corp
Publication of DE69431050D1 publication Critical patent/DE69431050D1/de
Application granted granted Critical
Publication of DE69431050T2 publication Critical patent/DE69431050T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
DE69431050T 1993-04-05 1994-04-05 PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN Expired - Fee Related DE69431050T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4287293A 1993-04-05 1993-04-05
PCT/US1994/003720 WO1994022861A1 (en) 1993-04-05 1994-04-05 PYRIDO[2,3-b][1,4]BENZODIAZEPINONES AS M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Publications (2)

Publication Number Publication Date
DE69431050D1 DE69431050D1 (de) 2002-08-29
DE69431050T2 true DE69431050T2 (de) 2003-03-13

Family

ID=21924192

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431050T Expired - Fee Related DE69431050T2 (de) 1993-04-05 1994-04-05 PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN

Country Status (11)

Country Link
US (1) US5712269A (de)
EP (2) EP0693070B1 (de)
JP (1) JP3638950B2 (de)
AT (1) ATE221067T1 (de)
AU (1) AU688318B2 (de)
CA (1) CA2159815A1 (de)
DE (1) DE69431050T2 (de)
DK (1) DK0693070T3 (de)
ES (1) ES2180575T3 (de)
PT (1) PT693070E (de)
WO (1) WO1994022861A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
ITMI991452A1 (it) * 1999-07-01 2001-01-01 Mediolanum Farmaceutici Srl Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
PE20010628A1 (es) * 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
CA2484384A1 (en) * 2002-04-19 2003-10-30 Takeda Pharmaceutical Company Limited Preventives for hiv infection
AU2005263578B2 (en) 2004-07-16 2010-09-02 Proteosys Ag Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2012511027A (ja) 2008-12-04 2012-05-17 チョンシー ユー 高透過性組成物およびその用途
WO2010081825A2 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as an agent in cancer treatment
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH438343A (de) * 1962-11-08 1967-06-30 Thomae Gmbh Dr K Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen
DE3735895A1 (de) * 1987-10-23 1989-05-03 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3818299A1 (de) * 1988-05-30 1989-12-07 Thomae Gmbh Dr K Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9000302D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Muscarinic receptor antagonists
DE4112014A1 (de) * 1991-04-12 1992-10-15 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung

Also Published As

Publication number Publication date
EP0693070B1 (de) 2002-07-24
AU6626194A (en) 1994-10-24
DE69431050D1 (de) 2002-08-29
EP0693070A1 (de) 1996-01-24
PT693070E (pt) 2002-12-31
ES2180575T3 (es) 2003-02-16
CA2159815A1 (en) 1994-10-13
ATE221067T1 (de) 2002-08-15
JP3638950B2 (ja) 2005-04-13
EP1120416A1 (de) 2001-08-01
AU688318B2 (en) 1998-03-12
US5712269A (en) 1998-01-27
DK0693070T3 (da) 2002-11-11
WO1994022861A1 (en) 1994-10-13
JPH08510999A (ja) 1996-11-19

Similar Documents

Publication Publication Date Title
LV10262B (en) Process for producing pharmaceutical compounds
HK1028206A1 (en) Use of four k-252a derivatives
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
TWI224595B (en) New benzazepine derivatives, drugs containing these and use of the same for producing drugs
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
PL320822A1 (en) Sulphonamidic compounds as therapeutic agents for treatment of central nervous system, method of obtaining novel sulphonamidic compounds and drugs containing such compounds
EP0769947A4 (de) Indolinonverbindungen zur behandlung von krankheiten
DE69431050D1 (de) PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
EP0436831A3 (en) Imidazo(1,2-a)pyridinylalkyl compounds for treatment of neurotoxic injury
EP0457671A3 (en) Dipyridamide for the treatment of diseases of the central or peripheral nervous system
CS53688A2 (en) Method of new substituted 3-phenyl-7h-thiazolo/3,2-b//1,2,4/triazine -7-ons production
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
FR2695388B1 (fr) Dérivés de 1,3,4-benzotriazépin-5(4H)-one et procédé pour leur préparation.
ES2062351T3 (es) Derivados de triazolo (4,5-c) piridina anticonvulsivos.
EP0593285A3 (en) Intermediates, and processes there to, for the preparation of 5,6-dihydropyrrolo(2,3-d)pyrimidines
GB9516021D0 (en) Process for the treatment of effluents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MANNKIND CORP. (N.D.GES.D. STAATES DELAWARE), DANB

8339 Ceased/non-payment of the annual fee